These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 30197173)

  • 1. Preliminary activity of capmatinib with gefitinib in NSCLC.
    Burki TK
    Lancet Oncol; 2018 Oct; 19(10):e517. PubMed ID: 30197173
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer.
    Wu YL; Zhang L; Kim DW; Liu X; Lee DH; Yang JC; Ahn MJ; Vansteenkiste JF; Su WC; Felip E; Chia V; Glaser S; Pultar P; Zhao S; Peng B; Akimov M; Tan DSW
    J Clin Oncol; 2018 Nov; 36(31):3101-3109. PubMed ID: 30156984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gefitinib with or without Transarterial Infusion Chemotherapy (Cisplatin) for Large Nonsmall Cell Lung Cancer with Epidermal Growth Factor Receptor Mutations.
    Zhang YQ; Jiang LJ; Jiang SX; Xu YF; Zhou BB; Huang GH; Liu DM; Wang Y; Fan WZ; Li JP; Wang B
    J Vasc Interv Radiol; 2019 Jul; 30(7):1004-1012. PubMed ID: 31171399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Capmatinib plus nazartinib in patients with EGFR-mutated non-small cell lung cancer.
    Felip E; Metro G; Soo RA; Wolf J; Solomon BJ; Tan DS; Ardizzoni A; Lee DH; Sequist LV; Barlesi F; Ponce-Aix S; Abreu DR; Campelo MRG; Sprauten M; Djentuh LO; Smith N; Jary A; Belli R; Glaser S; Zou M; Cui X; Giovannini M; Yang JC
    Eur J Cancer; 2024 Sep; 208():114182. PubMed ID: 38986421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term safety and survival with gefitinib in select patients with advanced non-small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP).
    Hirsch FR; Sequist LV; Gore I; Mooradian M; Simon G; Croft EF; DeVincenzo D; Munley J; Stein D; Freivogel K; Sifakis F; Bunn PA
    Cancer; 2018 Jun; 124(11):2407-2414. PubMed ID: 29579334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CNS efficacy of osimertinib in EGFR-mutated advanced NSCLC.
    Gourd E
    Lancet Oncol; 2018 Oct; 19(10):e516. PubMed ID: 30197172
    [No Abstract]   [Full Text] [Related]  

  • 7. Molecular selection trumps clinical selection.
    Shepherd FA
    J Clin Oncol; 2011 Jul; 29(21):2843-4. PubMed ID: 21670452
    [No Abstract]   [Full Text] [Related]  

  • 8. First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression.
    Schuler M; Tan EH; O'Byrne K; Zhang L; Boyer M; Mok T; Hirsh V; Yang JC; Lee KH; Lu S; Shi Y; Kim SW; Laskin J; Kim DW; Arvis CD; Kölbeck K; Massey D; Märten A; Paz-Ares L; Park K
    J Cancer Res Clin Oncol; 2019 Jun; 145(6):1569-1579. PubMed ID: 30783814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Capmatinib for the treatment of non-small cell lung cancer.
    Vansteenkiste JF; Van De Kerkhove C; Wauters E; Van Mol P
    Expert Rev Anticancer Ther; 2019 Aug; 19(8):659-671. PubMed ID: 31368815
    [No Abstract]   [Full Text] [Related]  

  • 10. Fuzheng Kang'ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial.
    Yang XB; Wu WY; Long SQ; Deng H; Pan ZQ; He WF; Zhou YS; Liao GY; Li QP; Xiao SJ; Cai JZ
    Trials; 2015 Apr; 16():146. PubMed ID: 25873045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.
    Soria JC; Wu YL; Nakagawa K; Kim SW; Yang JJ; Ahn MJ; Wang J; Yang JC; Lu Y; Atagi S; Ponce S; Lee DH; Liu Y; Yoh K; Zhou JY; Shi X; Webster A; Jiang H; Mok TS
    Lancet Oncol; 2015 Aug; 16(8):990-8. PubMed ID: 26159065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations.
    Cheng Y; Murakami H; Yang PC; He J; Nakagawa K; Kang JH; Kim JH; Wang X; Enatsu S; Puri T; Orlando M; Yang JC
    J Clin Oncol; 2016 Sep; 34(27):3258-66. PubMed ID: 27507876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
    Li F; Zhu T; Cao B; Wang J; Liang L
    Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alectinib shows CNS efficacy in ALK-positive NSCLC.
    Gourd E
    Lancet Oncol; 2018 Oct; 19(10):e520. PubMed ID: 30245054
    [No Abstract]   [Full Text] [Related]  

  • 15. A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment.
    Delord JP; Argilés G; Fayette J; Wirth L; Kasper S; Siena S; Mesia R; Berardi R; Cervantes A; Dekervel J; Zhao S; Sun Y; Hao HX; Tiedt R; Vicente S; Myers A; Siu LL
    Invest New Drugs; 2020 Dec; 38(6):1774-1783. PubMed ID: 32410080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Inhibitors of the epidermal growth factor receptor (EGFR) tyrosine kinase: similarity and differences].
    Lokiec F; Douillard JY
    Rev Pneumol Clin; 2011 Jun; 67 Suppl 1():S15-9. PubMed ID: 21777761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFR-TK1-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients with NSCLC: When Is it Worth The Risk?
    Mormile R
    Pathol Oncol Res; 2019 Oct; 25(4):1665-1666. PubMed ID: 30661223
    [No Abstract]   [Full Text] [Related]  

  • 18. Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC.
    Tan EH; Lim WT; Ahn MJ; Ng QS; Ahn JS; Shao-Weng Tan D; Sun JM; Han M; Payumo FC; McKee K; Yin W; Credi M; Agarwal S; Jac J; Park K
    Clin Pharmacol Drug Dev; 2018 Jun; 7(5):532-542. PubMed ID: 29346833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intracranial Activity of Gefitinib and Capmatinib in a Patient with Previously Treated Non-Small Cell Lung Cancer Harboring a Concurrent EGFR Mutation and MET Amplification.
    Gainor JF; Stevens SE; Willers H; Shih HA; Heist RS
    J Thorac Oncol; 2020 Jan; 15(1):e8-e10. PubMed ID: 31864558
    [No Abstract]   [Full Text] [Related]  

  • 20. Clairvoyance or reliable prediction of the future?
    van Zandwijk N; van de Vijver MJ
    Ann Oncol; 2007 Mar; 18(3):407-8. PubMed ID: 17322538
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.